© 2024. 代谢相关脂肪性肝病临床科研与疾病管理大数据共享平台
| 论文标题 | 作者 | 发表时间 | 发表杂志 | 影响因子 |
|---|---|---|---|---|
| Fructose-sweetened beverages induce diurnal redox dysregulation in pediatric MASLD | Helaina E Huneault, Scott E Gillespie,Zachery R Jarrell,Shasha Bai,Ana Ramirez Tovar, Cristian Sanchez-Torres,Lucia A Gonzalez-Ramirez,Kelsey C Chatman,Thomas R Ziegler,Dean P Jones, Jean A Welsh,Miriam B Vos |
2026-01 |
Redox biology |
11.9 |
| Updates in clinical medicine: MASLD in children and adolescents | Sander Lefere,Bart G P Koot,Jake P Mann,Philip Bufler,Ruth De Bruyne,Christian A Hudert |
2026-02 |
Journal of hepatology |
33 |
| Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts | Huangxin Zhu,Lihua Liu,Sicheng Yang,Yunfeng Fu,Yating Pan,Qingan Fu,Fan Du,Xiaodong Zhou |
2026-01 |
Cardiovascular diabetology |
10.6 |
| Hypoxia in MASLD: a spatial determinant of the pathogenesis | Isabel Fuster-Martínez,Vanesa Bernal-Monterde,Guillaume Bidault, José M. Arbonés-Mainar,Antonio Vidal-Puig |
2026-01 |
Trends in molecular medicine |
13.8 |
| Discovery of a carboxyl fullerene derivative as a new lipid droplet regulator inhibiting MASLD | Toujun Zou, Juan Wan , Rufang Liao, Lan Bai,, Xinyan Li,, Xu Cheng Junjie Zhou, Qinchao Tang, Yufeng Zhang, Chong Zhao, Weiyi Qu, jinjie Yang Xiang Zhang, Tian Tian, Xinxin Yao, Zhiwei Cai, Song Tian, Jingwei jiang, Yufeng Hu, Hailong Yang, Ejuan Zhang, Yun Chen, Binggiong Yu, jingjing cai ,Xiao-Jing Zhang, Zhi-Gang She, Hongliang Li,Haibo Xu 11 , Chunru Wang |
2026-01 |
Gut |
25.8 |
| Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts | Zhenyu Huo,Yijun Chen,Yating Huang,Yujun Long,Qian Zhang,Shuohua Chen,Guodong Wang,Shengtao Zhu,Dianjianyi Sun,Canqing Yu,Jun Lv,Liming Li,Ming-Hua Zheng,Shouling Wu,Yuanjie Pang,Shanshan Wu |
2026-03 |
Gut |
25.8 |
| Low anti-Mullerian hormone in reproductive age is associated with MASLD in midlife | Katherine M Cooper，Melissa Wellons，James G Terry， Heather G Huddleston，Marcelle I Cedars，Stephanie S Maldonado ，Monika Sarkar |
2026-02 |
Hepatology communications |
4.6 |
| Targeting THR β for MASLD Treatment: Current Progression and Emerging Prospects | Li J, Chen R, Zhang J, He J, Wang Y, Li Y |
2026-01 |
Journal of medicinal chemistry |
6.8 |
| Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis | Zobair M YounossiFatema NaderDominic LabriolaRebecca TaubAndrei RacilaLinda HenryMaria Stepanova |
2026-02 |
Hepatology communications |
4.6 |
| Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night | Marjot T, Smith K, Westcott F, White S, Johnson E, Srnic N, Barrett A, Hall E, Gralton K, Dennis K, Miller H, Pofi R, Cobbold JFL, Richmond R, Karpe F, Blazev R, Watt MJ, Parker BL, Hodson L, Ray DW, Tomlinson JW |
2026-01 |
Cell metabolism |
30.9 |
